Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Xiaodong Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5290-9705; OpenAlex author ID A5025489287. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Correction: Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. First author DOI 10.1038/s41419-023-06399-3↗
  2. Post-translational modification of CDK1-STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties. Co-author DOI 10.1186/s13578-023-01118-z↗
  3. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. First author DOI 10.1038/s41419-020-03019-2↗
  4. Pancreatic cancer-derived exosomes induce apoptosis of T lymphocytes through the p38 MAPK-mediated endoplasmic reticulum stress. Co-author DOI 10.1096/fj.201902186r↗
  5. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000308↗
  6. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. First author DOI 10.1038/s41419-019-1366-y↗
  7. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway. Co-author DOI 10.1089/jir.2018.0070↗
  8. MicroRNA-204 attenuates the migration and invasion of pancreatic cancer cells by targeting ZEB1/EMT axis. Last author PMID 31949767↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guoping Ding · 7 shared papers, 2018–2024 · strength 0.97
  2. Shengnan Jia · 5 shared papers, 2018–2024 · strength 0.75
  3. Liping Cao · 6 shared papers, 2018–2023 · strength 0.72
  4. Liping Cao · 1 shared paper, 2024 · strength 0.26
  5. Tao Shen · 2 shared papers, 2020 · strength 0.22
  6. Mingjie Zhang · 2 shared papers, 2018–2020 · strength 0.19
  7. Yimin Ding · 1 shared paper, 2023 · strength 0.18
  8. Huihan Zhang · 1 shared paper, 2018 · strength 0.14
  9. Dongnan Ping · 1 shared paper, 2020 · strength 0.12
  10. Dan Li · 1 shared paper, 2020 · strength 0.12
  11. Zhengrong Wu · 1 shared paper, 2020 · strength 0.12
  12. Xiaofan Pu · 1 shared paper, 2020 · strength 0.12
  13. Xu Dong Sun · 1 shared paper, 2020 · strength 0.10
  14. Qiang Yan · 1 shared paper, 2020 · strength 0.10
  15. Liangjing Zhou · 1 shared paper, 2018 · strength 0.09
  16. Ting Zhao · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.